Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions
Brief summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit, taking up resources such as nursing time and hospital space. Chronic treatment is required in most cases.
Detailed description
The proposed trial will be an exploratory, open-label, single-centre, phase IIIb safety, tolerability and efficacy study, wherein each patient acts as their own control. The primary outcome measure is safety and tolerability of panzyga in patients with active CIDP at standard and high infusion rates as measured by: * Occurrence of all adverse events with focus on adverse drug reactions (ADRs) * The secondary outcomes include: Patients' treatment satisfaction, proportion of patients successfully achieving higher infusion rates, health utilities associated with treatment, proportion of responders to treatment based on change in clinical scores, grip strength, and quality of life measures. The total sample size is 25-30 patients, based on a difference of 30% in adverse events rates between the standard infusion rate and the maximum rate tolerated by each patient.
Interventions
DRUGImmune Globulin 10% Intravenous Solution
standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
Sponsors
Vera Bril
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Each patient with active CIDP will receive Panzyga (immune globulin) at standard and high infusion rates and will act as their own control.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with diagnosis of definite or probable CIDP according to the EFNS/PNS Guideline 2010; including patients with Multifocal Acquired Demyelinating Sensory And Motor Neuropathy (MADSAM) or pure motor CIDP 2. Patients with active disease, i.e. not being in remission. 3. IVIG naïve patients with clinical indication for IVIG based on progressive or relapsing disease and adjusted INCAT (ONLS) disability score between 2 and 9 (with a score of 2 coming exclusively from leg disability). 4. Patients already receiving IVIG must be on 3- or 4-weekly IVIG treatment schedule with a calculated monthly dosage between 0.8 g/kg and 2.0 g/kg BW 5. ≥ 18 years of age 6. Voluntarily given, fully informed written consent obtained from patient before any study-related procedures are conducted 7. For enrolment into the Second Phase: At each of the last three infusions in the First Phase, administration of panzyga® had to be at the maximum infusion rate of 0.08 mL/kg/min and good tolerated- assessment by Investigator according to local site practice
Exclusion criteria
1. MMN with conduction block 2. Patients who previously failed immunoglobulin therapy 3. Treatment with immunomodulatory/suppressive agents (cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil or azathioprine) during the six months prior to baseline visit 4. Patients on or treated with rituximab, alemtuzumab, cyclophosphamide, or other intensive chemotherapeutic regimens, previous lymphoid irradiation or stem cell transplantation during the 12 months prior to baseline visit 5. Respiratory impairment requiring mechanical ventilation 6. Myelopathy or evidence of central nervous system demyelination or significant persisting neurological deficits from stroke, or central nervous system (CNS) trauma 7. Clinical evidence of peripheral neuropathy from another cause such as 1. connective tissue disease or systemic lupus erythematosus (SLE) 2. HIV infection, hepatitis, Lyme disease 3. cancer (with the exception of basal cell skin cancer) 4. IgM paraproteinemia with anti-myelin associated glycoprotein antibodies 8. Diabetic neuropathy 9. Cardiac insufficiency (New York Heart Association \[NYHA\] III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease 10. Severe liver disease (ALAT 3x \> normal value) 11. Severe kidney disease (creatinine 1.5x \> normal value) 12. Hepatitis B, hepatitis C or HIV infection 13. Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever; patients with susceptibility to embolism or DVT 14. Body mass index (BMI) ≥40 kg/m2 15. Selective IgA deficiency with known anti-IgA antibodies 16. History of hypersensitivity, anaphylaxis or severe systemic response to immuno-globulin, blood or plasma derived products, or any component of panzyga® 17. Known blood hyperviscosity, or other hypercoagulable states 18. Use of other blood or plasma-derived products within three months prior to enrolment 19. Patients with a past or present history of drug abuse or alcohol abuse within the preceding five years prior to baseline visit 20. Patients unable or unwilling to understand or comply with the study protocol 21. Participation in another interventional clinical study with IMP treatment currently or during the three months prior to enrolment 22. Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner) while on study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of all adverse events with focus on adverse drug reactions (ADRs) | 2 years | adverse drug reactions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| proportion of patients successfully achieving higher infusion rates | 2 years | descriptive analysis of number of patients |
| health utilities | 2 years | completion of questionnaire |
| treatment satisfaction | 2 years | completion of questionnaire |
| grip strength | 2 years | measurements in kPa |
| quality of life measures | 2 years | completion of scale |
| proportion of responders to treatment based on change in clinical scores | 2 years | completion of scale |
Countries
Canada
Outcome results
None listed